CA2388610C - Oral transmucosal drug dosage using solid solution - Google Patents

Oral transmucosal drug dosage using solid solution Download PDF

Info

Publication number
CA2388610C
CA2388610C CA002388610A CA2388610A CA2388610C CA 2388610 C CA2388610 C CA 2388610C CA 002388610 A CA002388610 A CA 002388610A CA 2388610 A CA2388610 A CA 2388610A CA 2388610 C CA2388610 C CA 2388610C
Authority
CA
Canada
Prior art keywords
dosage form
drug
solid dosage
solid
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002388610A
Other languages
French (fr)
Other versions
CA2388610A1 (en
Inventor
Hao Zhang
Jed Croft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Anesta LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23697434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2388610(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anesta LLC filed Critical Anesta LLC
Publication of CA2388610A1 publication Critical patent/CA2388610A1/en
Application granted granted Critical
Publication of CA2388610C publication Critical patent/CA2388610C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats

Abstract

The present invention is directed toward formulation and method for oral transmucosal delivery of a pharmaceutical.
The invention provides a drug formulation comprising a solid pharmaceutial agent in solid solution with a dissolution agent. The formulation is administered into a patient's oral cavity, delivering the pharmaceutical agent by absorption through a patient's oral mucosal tissue. The formulation and method provide for improved oral mucosal delivery of the pharmaceutical agent.

Description

ORAL TRANSMUCOSAL DRUG DOSAGE
USING SOLID SOLUTION
BACKGROUND
Field of the Invention The present invention relates to the improvement of oral transmucosal drug delivery systems. In particular, the invention relates to solid pharmaceutical dosage forms for oral transmucosal delivery of pharmaceutically active substances, and more particularly, to solid dosage forms producing higher dissolution rates and accordingly, higher absorption rates of the pharmaceutically active substance. Furthermore, the present invention provides improved solubility in saliva and mucosal absorption without compromising stability of the solid dosage form during storage.
Description of the Prior Art Solid pharmaceutical dosage forms are well known in the art. Compared to other dosage forms, such as solutions (oral or injection) and vapor or gas inhalation, the oral solid dosage forms are the most preferred dosage forms and they account for eighty percent of all the pharmaceutical products on the market. Solid dosage forms are easier for patient or caregiver to identify, handle and administer. They are also non-invasive and have high patient compliance.
With respect to drug delivery routes, solid dosage forms can be further divided into several groups, gastrointestinal (GI) tract delivery, suppository (rectal, vaginal and urethral) delivery and oral transmucosal delivery. The majority of solid dosage forms on the market are designed for gastro-intestinal delivery. GI delivery is often referred to simply as "oral delivery." Solids are also commonly delivered as suppositories such as laxatives, contraceptives and hemorrhoid medication. Relatively few drug formulations are designed as solid dosage forms intended to deliver a drug through the oral mucosa.
Two such drug formulations are Oralet and Actiq .
Despite the overall popularity of other delivery methods, oral transmucosal (OT) delivery is a particularly advantageous delivery route. One of the advantages of OT
delivery is that it is a non-invasive drug delivery method. Furthermore, OT
delivery has better patient compliance, less risk of infection and lower cost than invasive procedures such as injection and implantation. It also has much shorter onset time, i.e., the time from administration to therapeutic effect, than does oral delivery. A drug absorbed via the oral mucosa will also avoid first pass metabolism, in which the drug is metabolized in the GI
2 tract and liver. Oral transmucosal delivery is simple and can be administered by the caregiver or the patient with minimal discomfort.
Various solid dosage forms, such as sublingual tablets, troches, lozenges, lozenges-on-a-stick, chewing gums, and buccal patches, have been used to deliver drugs via the oral mucosal tissue. United States Patent 5,711,961 to Reiner, et al.
discloses a chewing gum for the delivery of phannaceuticals. The chewing gum delivery dosage form of Reiner is primarily directed for patients who may be more disposed to self-administer a drug in chewing gum form as opposed to other less familiar dosage forms.
The gum may also be used to mask the taste of various pharmaceutical ingredients.
Reiner also discloses the use of the gum formulation to extend the duration of drug delivery.
Transmucosal delivery of drugs is also accomplished through the use of patches which are attached using an adhesive to mucosal surfaces in the oral cavity.
Oral transmucosal delivery using a buccal patch is disclosed in United States Patent No.
5,298,256 to Flockhart, et al. The buccal patch may be designed as a "closed"
delivery system, that is, the environmental conditions inside the patch are primarily controlled by the formulation. Employing a closed delivery system can facilitate drug delivery, such as allowing the use of enhancers or other permeability facilitators in the formulation which might otherwise be impractical. In an "open" delivery system, such as lozenges or sublingual tablets, the drug delivery conditions are influenced by the conditions of the surrounding environment, such as rate of saliva secretion, pH of the saliva, or other conditions beyond the control of the formulation. Buccal patch delivery also displays a pharmacokinetic delivery profile that can mimic a short term IV infusion.
Solid dosage forms such as lozenges and tablets are commonly used for oral transmucosal delivery of pharmaceuticals. For example, nitroglycerin sublingual tablets have been on the market for many years. The sublingual tablets are designed to deliver small amounts of the potent nitroglycerin, which is almost immediately dissolved and absorbed. On the other hand, most lozenges or tablets are typically designed to dissolve in the mouth over a period of at least several minutes which allows extended dissolution of the lozenge and absorption of the drug.
A lozenge-on-a-stick dosage form of transmucosal drug delivery is disclosed in United States Patent No. 4,671,953 to Stanley, et al. In addition to being non-invasive and providing a particularly easy method of delivery, the lozenge-on-a-stick dosage form allows a patient or caregiver to move the dose in and out of the mouth to titrate the dose.
This practice is called dose-to-effect, in which a patient or caregiver controls the administration of the dose until the expected therapeutic effect is achieved.
This is
3 particularly important for certain symptoms, such as pain, nausea, motion sickness, and premedication prior to anesthesia because each patient needs a different amount of medication to treat these symptoms. For these types of treatments, the patient is the only one who knows how much medication is enough. Once the appropriate amount of drug is delivered, the patient or caregiver can remove the lozenge, thus, stopping the drug delivery to prevent overdose.
Solid dosage units are made in a number of ways. In a high volume manufacturing facility, solid dosage units can be made by direct compression, injection molding, freeze-drying or other solid processing techniques. Compression, by far, is the most commonly used manufacturing process in making solid dosage units. A
typical formulation of solid dosage form consists of active ingredient(s), bulking agent(s), binder(s), flavor(s), lubricant(s) and other excipients.
To benefit from the advantages of oral transmucosal delivery, solid dosage forms must be formulated to take into account the oral cavity's unique environment.
In certain aspects, the unique environment of the oral cavity can complicate the transmucosal delivery of the drug. For example, one of the significant aspects of the oral cavity environment with regard to its use as a drug administration route is that there is relatively little solvent into which a solid dosage form can dissolve. Furthermore, the relative amounts of saliva produced in given circumstances can vary widely. On the average, salivary glands produce between 800 to 1500 ml saliva a day. In a resting, unstimulated state, salivary glands produce about 0.5 ml mucous-type saliva per minute, while stimulated salivary glands produce about 1 to 3 ml per minute. During the time required for solid dose drug delivery, about 10 to 15 minutes, the total amount of saliva produced is 10 to 15 ml, which is a small volume compared to 600 to 1000 ml of potential solvent produced in the GI tract.
Similarly, there is a limited period of time during which the solid dosage form can be dissolved and absorbed. An orally (GI tract) delivered solid dose will remain in the GI tract for several hours. An oral transmucosal dose remains in the oral cavity for a mere 10 to 15 minutes. During this period, the solid unit has to be dissolved, and the drug must be released and absorbed. This is a major challenge for formulating the transmucosal solid dosage form.
The absorption of a drug across the mucosal tissue can be described using the equation of Fick's first law:

d4 DK
dt h p - (cl -C2) * S
4 where dA is the amount of drug delivered over time dt, Kp is the partition coefficient of the drug between oral mucosal tissue and the drug solution, D is the diffusion coefficient of the drug inside the oral mucosal tissue, S is the surface area of the oral cavity, h is the thickness of the oral mucosal tissue, C, and C2 are the drug concentrations in the solution and blood circulation, respectively.
The capacity of the oral transmucosal delivery is limited in large part by the surface area available for drug absorption. The surface area in the oral cavity is 200 cm2, which is relatively small compared to the surface area of other drug delivery routes, such as the GI tract (350,000 cmZ) and skin (20,000 cm2).
The contact time between the drug and the absorption surface is primarily controlled by the dissolution rate of the solid unit. Once the solid unit is dissolved, any drug solution not yet absorbed will be swallowed, thereby ending further OT
drug absorption. Generally the time a solid unit can remain in the oral cavity is between 10 to minutes, but this time period is quite variable and depends upon a number of factors.
15 Some of the factors affecting the contact time are difficult to account for, such as how vigorously a patient will suck on the dosage form.
In addition to the difficulties presented by the oral cavity's unique environment, the physicochemical properties of the drug can present challenges and complications that affect oral transmucosal drug delivery. Primarily, the solubility, the dissolution rate, and the partition coefficient determine the extent to which a drug can be delivered via the oral mucosal tissue. Solubility and dissolution rate are key aspects in creating the concentration gradient, which is the driving force for drug delivery.
Partition coefficient, on the other hand, acts like an amplifier, such that the drug delivery rate is directly proportional to the partition coefficient up to a point.
The solubility of a drug is an inherent characteristic of the drug in a particular solvent. The relative affinities of the solute molecules and the solid phases determine the solubility. In other words, the inter-molecular attractions between the solvent-solute and solute-solute molecules will largely determine solubility. The solubility of a drug is a specific thermodynamic property, that is, it describes the chemical state of the drug.
Imbalance in a thermodynamic state will cause the change toward re-establishing a balance within the system. Because solubility is a specific thermodynamic quantity, any imbalance that causes a change away from solubility equilibrium will result in a change in the system toward re-establishing balance.
The partition coefficient is the concentration ratio of a drug between two phases.
Partition coefficient is determined largely by the inherent properties of the drug. In the case of oral transmucosal delivery, the attraction of drug molecules between two phases on the solution/tissue interface determines the partition coefficient of the drug. As with solubility, partition coefficient is a thermodynamic property and any imbalance will cause a change toward re-establishing a balanced state.
The effectiveness of drug formulations is dependent upon the time frame imposed
5 on the drug reaction. The dissolution rate of the drug, unlike the solubility and partition coefficient, is a kinetic property of a drug. An otherwise effective drug may have a dissolution rate which is acceptable for one delivery method but which is too slow for the particular time frame of another. For example the dissolution rate of a drug may be acceptable for GI delivery, but the dissolution rate may not be practical for oral transmucosal delivery. The time frame in oral transmucosal delivery is 10 to 15 minutes rather than 4 to 6 hours in the GI tract.
To a certain extent, the physicochemical properties of a drug can be manipulated by changing the surrounding environment. For example, the solubility of an ionizable drug can be greatly increased by changing the pH of the solution to a value at which the drug is in its ionized form. However, attempts to advantageously manipulate one particular physicochemical property can have a negative impact on another property. For instance, in designing a solid drug formulation, a pharmacist may attempt to increase the drug absorption by manipulating pH, but the altered pH negatively impacts other aspects of the formulation, such as the partition coefficient of the drug. Designing a solid, oral transmucosal formulation can be further complicated when a potentially effective solid formulation is unstable in storage and thereby rendered impractical for commercial use.
There are several ways drug designers attempt to increase solubility and dissolution rate. A common practice in the pharmaceutical industry is to use a co-solvent.
Many drugs that are insoluble in aqueous media are more soluble in organic solvents.
Formulations designed for intravenous injections often employ co-solvents to increase the solubility of drugs. However, solid dosage forms, by their nature, cannot be formed with co-solvents solubility.
Some relatively insoluble drugs can be combined with other molecules to form more soluble complexes. Cyclodextrins, for example, have been used in many formulations to increase the solubility ofpoorly soluble, hydrophobic drugs.
Derivatized cyclodextrins are donut shaped molecules with a hydrophobic interior and hydrophilic exterior. Hydrophobic drugs can be sheltered inside the cyclodextrin cavity, and thus become soluble in the aqueous media.
One significant drawback to complexing is that once a drug molecule is complexed with another molecule, such as a hydrophobic drug inside a cyclodextrin, the drug is no longer a free molecule. In other words, complexing the drug allows the drug
6 to go into solution, however, the complex often has poor absorption characteristics. This is often the case with cyclodextrin-complexed drugs. The drug alone may be capable of being absorbed, but due to its larger size, the drug/cyclodextrin complex is too large to be absorbed through the mucosa.
For weak acids or weak bases, which are ionizable, there is yet another way to manipulate the solubility and dissolution rate. The weak acid or weak base can react with base or acid, respectively, to form a salt. The ionized salt forms will almost always have higher solubilities and dissolution rates than the unionized forms. In many cases, they are also more stable chemically or physically. However, the ionized forms almost always have lower partition coefficients than the unionized forms, and therefore are less well absorbed by the oral mucosal tissue. Thus, converting the weak acid or base to an ionized form in order to increase solubility compromises absorption.
A common method of controlling the pH of the formulation is to use a buffer system. A buffer system consists ofhydrogen ion donor(s) (acid) and conjugate hydrogen ion receiver(s) (base). An appropriate buffer system stabilizes the pH.
However, optimizing the pH generally compromises the solubility and partition coefficient for oral transmucosal drug delivery.
It would be advantageous to design a solid oral transmucosal dosage that would allow for increased dissolution, solubility and stability of the drug and yet preserve the drug absorption rate. It would also be advantageous to provide a formulation concept and manufacturing processes for making solid dosage units embodying the foregoing attributes.

BRIEF SUMMARY OF THE INVENTION
In view of the foregoing, at least one embodiment of the present invention provides a method and formulation for oral transmucosal drug delivery of a solid that takes into account the unique environment of the oral cavity.
At least one embodiment of the present invention provides a method and formulation for oral transmucosal delivery of a solid that allows for improved dissolution.
Also, at least one embodiment of the present invention provides a method and formulation for oral transmucosal delivery of a solid that allows for improved stability of the formulation in storage.
Furthermore, at least one embodiment of the present invention provides a method and formulation for oral transmucosal delivery of a solid that provides for increased absorption of the drug through the oral mucosal tissues.
7 At lease one embodiment of the present invention provides a method and formulation for oral transmucosal delivery of a solid that allows for better control of dissolution of pharmaceutical agents.
It addition, at least one embodiment of the present invention provides a method and formulation for oral transmucosal delivery of a solid that does not compromise stability in storage to improve absorption.
The present invention comprises a pharmaceutical agent or drug which is capable ofbeing absorbed into the tissues of the oral cavity or into the circulatory system through oral mucosal tissue. The pharmaceutical agent or drug is in solid form and is combined with a dissolution agent also in solid form, yielding a solid solution. The solid solution formulation maybe further combined with buffers and other excipients as needed in order to facilitate the drug's manufacturing, storage, administration and delivery through oral mucosal tissue. The formulation can be used with a variety of oral transmucosal delivery dosage forms, such as a tablet, lozenge, lozenge on a stick, chewing gum, and buccal or mucosal patch.
The present invention is designed to work effectively in the unique environment of the oral cavity such that the limited amount of solvent, the relatively short period of time for drug delivery, and the pH levels within the oral cavity do not significantly deter absorption of the drug. The formulation is also designed to improve dissolution, solubility, and stability of the drug in solid solution. The advantages of the present invention contribute to the ability of the drug formulation to provide higher levels of drug absorption in oral transmucosal delivery.

BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing features of the present invention will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. Understanding that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope, the invention will be described with additional specifics and detail through use of the accompanying drawings in which:
Figure 1 is a graph showing the serum drug concentration - time profile of piroxicam as delivered by the present invention compared to delivery using the prior art;
Figure 2 is a graph showing the plasma drug concentration - time profile of droperidol as delivered by the present invention compared to delivery using the prior art;
and
8 PCT/US00/28113 Figure 3 is a graph showing the serum drug concentration - time profile of etomidate as delivered by the present invention compared to delivery using the prior art.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
It will be readily understood that the components of the present invention, as generally described and illustrated in the Figures herein, could be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of the embodiments of the formulation and method of the present invention, as represented in Figures 1 through 3, is not intended to limit the scope of the invention, as claimed, but is merely representative of the presently preferred embodiments of the invention.
The present invention relates to novel methods and formulations for making solid dosage forms for oral transmucosal drug delivery. More specifically, the present invention relates to methods and formulations for making a solid solution formulation for oral transmucosal drug delivery. The present invention provides a number of advantages over the prior art formulations. The solid solution formulation comprises a pharmaceutical agent or drug capable of being delivered via the oral mucosal membrane and a dissolution agent(s) capable of being mixed with the pharmaceutical agent at the molecular level. Other pharmaceutical ingredients may be added to the formulation as necessary. The solid solution formulation provides for improved dissolution rate, solubility, and stability, and ultimately improved oral transmucosal drug delivery.
The pharmaceutical agent of the present invention may be any drug substance, which is used for diagnosis, prevention, control, and treatment of physiological, pathological and psychological conditions. It is understood that a considerable variety of drug classes and specific drugs may be used as the pharmaceutical agent or agents of the present invention. The drug classes can include without limitation: androgens, estrogens, non-steroidal anti-inflammatory agents, anti-hypertensive agents, analgesic agents, anti-depressants, antibiotics, anti-cancer agents, local anesthetics, antiemetics, antiinfectants (antiinfectives), contraceptives, antidiabetic agents, steroids, antiallergy agents, antimigraine agents, agents for smoking cessation, and antiobesity agents.
Specific drugs can include without limitation piroxicam, droperidol, etomidate, nicotine, testosterone, estradiol, nitroglycerin, clonidine, dexamethasone, wintergreen oil, tetracaine, lidocaine, fentanyl, sufentanil, progesterone, insulin, Vitamin A, Vitamin C, Vitamin E, prilocaine, bupivacaine, sumatriptan, dihydroergotamine, COX2 inhibitors, and peptides.
The selection of dissolution agent or agents will be determined by the pharmaceutical agent, as well as the process used in making the solid solution and
9 characteristics of its intended use. (e.g., taste for OT delivery). A primary function of the dissolution agent is to combine with the pharmaceutical agent to form a solid solution. Therefore, the dissolution agent and the pharmaceutical agent must be able to mix at the molecular level. For example, if the co-melt process is used to make a solid solution, the dissolution agent must be capable of acting as a solvent into which the pharmaceutical agent can dissolve or melt. If a partial wet granulation process is used, the dissolution agent and the pharmaceutical agent must be able to dissolve in the proper solvent for this process.
The dissolution agent may also enhance stability of the pharmaceutical agent.
Since the dissolution agent is mixed with the pharmaceutical agent at the molecular level, it also provides a physical barrier for preventing the pharmaceutical agent from being contacted by other chemicals in the formulation or environment. For example, if the main degradation reaction of the pharmaceutical agent is hydrolysis, the use of a non-hygroscopic dissolution agent can block water from accessing the pharmaceutical agent.
Therefore, the hydrolytic degradation reaction is prevented.
A variety of pharmaceutical ingredients can be used as the dissolution agent, depending upon the pharmaceutical agent and other ingredients used in the formulation.
The dissolution agents include but are not limited to acacia, alginic acid, carbomer, carboxymethylcellulose, calcium, carboxymethylcellulose sodium, microcrystalline cellulose, cellulose, dextrates, dextrin, dextrose, ethylcellulose, fructose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactitol, lactose, lecithin, maltodextrin, mannitol, methylcellulose, poloxamer, polyethylene glycol, polymethacrylates, polyoxyethylene alkyl ethers, polyvinyl alcohol, povidone, propylene glycol alginate, sodium alginate, sodium ascorbate, sodium starch glycolate, sorbitol, starch, starch (pregelatinized), sucrose, tragacanth, trimethylglycine, xanthan gum, xylitol, and zein.
There are several ways to create a solid solution including, but not limited to, wet granulation, co-melt, spray drying, and freeze-drying.
In one embodiment of the present invention, a process of wet granulation is used to create the solid solution. The process of wet granulation can be outlined as several steps: weighing and blending of several ingredients in the presence of solvent(s), drying the mixture into solid, and milling the solid to proper size.
In the weighing and blending step of wet granulation, proper amounts of drug dissolution agent and solvent are mixed thoroughly. Additional ingredients may be added to facilitate the mixing of the ingredients. A key to this step is to find a solvent or solvents that both the drug and dissolution agent can dissolve into. The end result of this step is a finely blended mixture in which the drug and the dissolution agent are mixed at the molecular level.
The mixture is then dried and resized to powder so that it can be compressed into solid units. There are several ways to dry the wet granulation mixture depending on the 5 mixture, the solvent, and the equipment. Milling and screening steps are usually used to ensure the proper particle size distribution for compression.
The wet-granulated powder may further be mixed with other ingredients to form the whole formulation. In this case, the formulation is made by a partial wet-granulation process. A formulation made using partial wet-granulation provides a unique opportunity
10 for manufacturing ionizable compounds. As mentioned earlier, the dissolution rate, solubility, stability and permeability of an ionizable drug are greatly influenced by the pH of the system. In general, an ionized form of a drug has a higher dissolution rate and solubility, better stability, but lower permeability than does the unionized form. A partial wet granulation formulation can provide a special environment that facilitates the drug's dissolution in its local environment, yet controls the overall formulation to facilitate drug absorption. The key is the pH segregation in the solid formulation. The pH in wet granulated particles is adjusted so that the drug is ionized, i.e., low pH for a basic drug or high pH for an acidic drug. The pH in the whole formulation is adjusted so that the drug absorption is optimized. During storage, the drug is ionized and it is stable. Upon dissolution in the oral cavity, since the micro-environment of the drug favors the ionized form, the drug has a higher dissolution rate and solubility. Once the drug is in solution, the ionization of the drug is controlled by the overall environment, which is controlled by other constituents of the formulation.
In another embodiment of the present invention, a process of co-melting is used to create the solid solution. In this process, the dissolution agent is heated and melted. In its melted state, the dissolution agent can act as a solvent into which the drug is dissolved or co-melted. The mixture of drug and dissolution agent is then cooled and solidified.
The solid solution of drug and dissolution agent will be further processed into compressible powder. Other ingredients may also be added to the co-melted powder to complete the drug formulation, such as ingredients which allow additional pH
manipulation.
In yet another embodiment of the present invention, a process of freeze-drying is used to create the solid solution. In this process, the drug and dissolution agent are dissolved in aqueous solution. The solution is quickly frozen. The frozen solid is then put into a vacuum chamber where the water is removed from the solid via sublimation.
The resulting powder is a solid solution of drug and dissolution agent.
11 In yet another embodiment of the present invention, a process of spray-drying is used to create the solid solution. In this process, the drug and dissolution agent are dissolved in solution. The solution is then sprayed into a chamber. The solvent is evaporated while the droplets are in the air. The result is a fine powder consisting of drug and dissolution agent.
There are many other processes for making solid solution of drug and dissolution agent, (i.e. processes that mix the drug and dissolution agent at the molecular level). The selection of the process will mainly depend on the drug and dissolution agent.
The available equipment and cost will also play an important role in process selection.
The present invention provides for an increased dissolution rate of a drug using the solid solution in an oral transmucosal formulation. Because the drug is in the form of a solid solution, the dissolution rate is no longer determined by the characteristics of the drug itself, but by the dissolution profile of the solid solution. Since dissolution agents are usually selected because of their fast dissolution profiles, solid solution matrices usually dissolve quickly to release the drug in the oral cavity. The present invention provides a mechanism of controlling the drug dissolution and release by controlling the dissolution and disintegration rate of the solid unit.
The present invention may also provide for a higher solubility for certain drugs by forming a supersaturated solution upon dissolving. As mentioned earlier, the drug and dissolution agent in the form of a solid solution are mixed at the molecular level. The dissolution agents are usually selected based on their fast dissolution rate so that, upon dissolution of the dissolution agent, all the drug molecules will be in the solvent such that the drug concentration of the solution may exceed its solubility. A super saturated solution may exist until precipitation occurs. Precipitation can be viewed as three-step process: 1) the drug concentration in a solution becomes higher than its solubility; 2) drug nuclei form; and 3) the nuclei grows into crystals. More specifically, the drug concentration is a thermodynamic parameter and it determines whether crystals grow or dissolve. Nuclei form as the result of clustering of drug molecules, a kinetic process or as the result of clustering of molecules of some other solid in the solution.
Crystal growth is definitely a kinetic process and therefore, the overall process of precipitation is a time-dependent, kinetic process, which does not happen instantaneously. During the time between drug dissolution and precipitation, the concentration of the drug is higher than its solubility resulting in a solution that is supersaturated. Accordingly, the present invention provides a method of creating a supersaturated solution to improve the drug absorption.
12 The present invention may also provide for a way to stabilize the drug in the solid formulation. Because the drug is processed and resides in micro-environment within the whole drug formulation, it is possible to create a favorable micro-environment to promote drug stability, and to promote absorption of the drug by using the rest of formulation to create a favorable environment for drug absorption. Thus the solid solution drug formulation facilitates stability without compromising drug delivery. The segregated solid formulation is therefore a unique advantage of this invention.
In order for the present invention to operate effectively, it is necessary that the drug incorporated within the dissolvable matrix be capable of permeating the mucosal membrane either alone or by suitable adjustments in the environmental pH, or other chemical modification or in combination with a suitable permeation enhancer.
The present invention has applicability to a variety of drugs affecting the central nervous system. For example, the present invention may easily be utilized in the administration of opioid agonists (such as fentanyl, alfentanil, sufentanil, lofentanil, and carfentanil), opioid antagonists (such as naloxone and nalbuphene), butyrophenones (such as droperidol and haloperidol); benzodiazepines (such as Valium, midazolam, triazolam, oxazolam, and lorazepam); GABA stimulators (such as etomidate);
barbiturates (such as Thiopental, methohexital, thiamazol, pentobarbital, and hexabarbital); di-isopropylphenols drugs (such as diprivan); and other central nervous system-acting drugs such as levodopa. It will be appreciated that other drugs may also be utilized within the scope of the present invention either singly or in combination.
Table 1 lists some of the CNS-acting drugs which are suitable for incorporation into the present invention, as well as some of the characteristics of those drugs.

GENERIC DRUG DRUG CLASS DOSE RANGE
methohexital barbiturate 10-500 mg pentobarbital barbiturate 50-200 mg thiamylal barbiturate 10-500 mg thiopental barbiturate 50-500 mg fentanyl opioid agonist 0.05-5 mg alfentanil opioid agonist 0.5-50 mg sufentanil opioid agonist 5-500µg lofentanil opioid agonist 0.1-100µg carfentanil opioid agonist 0.2-100µg naloxone opioid antagonist 0.05-5 mg
13 GENERIC DRUG DRUG CLASS DOSE RANGE
nalbuphene opioid antagonist 1-50 mg diazepam benzodiazepine 1-40 mg lorazepam benzodiazepine 1-4 mg midazolam benzodiazepine 0.5-25 mg oxazepam benzodiazepine 5-40 mg triazolam benzodiazepine 250-1000 mg droperidol buterophenone 1-20 mg haloperidol buterophenone 0.5-10 mg propanidid eugenol 1-10 mg etomidate GABA stimulator 5-60 mg propofol substituted phenol 3-50 mg ketamine phencyclidine 5-300 mg diprivan substituted phenol 5-20 mg Drugs having effects on the cardiovascular and renal vascular systems may also be administered using the present invention. A few examples of such drugs are identified in Table 2.

GENERIC DRUG DRUG CLASS DOSE RANGE
bretylium antiarrhythmic 50-500mg captopril ACE inhibitor 25-75 mg clonidine antihypertensive 0.1-0.5 mg dopamine renal vascular 0.5-5 mg enalapril ACE inhibitor 5-15 mg esmolol antihypertensive/angina 100-250 mg furosemide diuretic 20-100 mg isosorbide angina 2.5-40 mg labetalol antihypertensive 100-400 mg lidocaine antiarrhythmic 50-250 mg metolazone diuretic 5-50 mg metoprolol antihypertensive 25-100 mg nadolol antihypertensive 40-160 mg nifedipine antihypertensive 10-40 mg
14 GENERIC DRUG DRUG CLASS DOSE RANGE
nitroglycerin antihypertensive/angina 0.4-1.0 mg nitroprusside hypotensive 10-50 mg propranolol antihypertensive/angina 0.1-50 mg In addition to the foregoing, there are many other drugs which can be administered using the present invention. Exemplary of such drugs are those identified in Table 3.

GENERIC DRUG DRUG CLASS DOSE RANGE
benzquinamide antiemetic 25-100 mg meclizine antiemetic 25-100 mg metoclopramide antiemetic 5-20 mg prochlorperazine antiemetic 5-25 mg trimethobenzamide antiemetic 100-2500 mg clotrimazole antifungal 10-20 mg nystatin antifungal 100,000-500,000 units cardidopa antiparkinson with levodopa 10-50 mg levodopa antiparkinson 100-750 mg sucralfate antisecretory 1-2 grams albuterol bronchodilator 0.8-1.6 mg aminophylline bronchodilator 100-500 mg beclomethasone bronchodilator 20-50µg dyphylline bronchodilator 100-400 mg epinephrine bronchodilator 200-500µg flunisolide bronchodilator 25-50µg isoetharine bronchodilator 170-680 mu.g isoproterenol HCI bronchodilator 60-260µg metaproterenol bronchodilator 0.65-10 mg oxtriphylline bronchodilator 50-400 mg terbutaline bronchodilator 2.5-10 mg theophylline bronchodilator 50-400 mg ergotamine antimigraine 2-4 mg methysergide antimigraine 2-4 mg propranolol antimigraine 80-160 mg suloctidil antimigraine 200-300 mg ergonovine oxytocic 0.2-0.6 MG

GENERIC DRUG DRUG CLASS DOSE RANGE
oxytocin oxytocic 5-20 units desmopressin acetate antidiuretic 10-50µg lypressin antidiuretic 7-14µg vasopressin antidiuretic 2.5-60 units 5 insulin antihyperglycemic 1-100 units In addition to the foregoing drugs, certain macromolecular drugs (such as .beta.-endorphin, enkephalins, bradykinin, aniotensin I, gonadotropic hormones, 10 adrenocorticotropic hormone (ACTH), calcitonin, parathyroid hormone, and growth hormone), polysaccharides (such as heparin), antigens, antibodies, and enzymes may be adapted for transmucosal administration within the scope of the present invention.
Pharmaceutical ingredients that can be used in the formulation of the present invention may include, but are not limited to, absorbents, buffering agents (such as
15 phosphate buffer, carbonate buffer, tris buffer, tartrate buffer, borate buffer, acetate buffer, or maleate buffer), colorants, flavorants, solvents and co-solvents, coating agents, direct compression excipients, disintegrants, glidants, lubricants, opaquants, polishing agents, suspending agents, sweetening agents, anti-adherents, binders, and capsule diluents, the ingredients may also include anti-fungal preservatives, antimicrobial preservatives, clarifying agents, emulsifying agents, antioxidants, levigating agents, plasticizers, surfactants, tonicity agents, and viscosity increasing agents.

Example 1 In one actual experiment, oral transmucosal delivery of a pharmaceutical agent using the present invention was compared with oral transmucosal delivery of the same pharmaceutical agent using a prior art technique of physically mixing the drug formulation. The drug formulation included the ingredients piroxicam, mannitol, Emdex (dextrates, hydrated), sodium hydroxide, and magnesium stearate in the weight percentages and amounts per unit shown in Table A.
16 TABLE A
Piroxicam Oral Transmucosal Delivery Formulation Ingredient % mg/2g Piroxicam 2% 40 Mannitol 10% 200 Emdex (dextrates, hydrated) 86.76% 1735.2 NaOH 0.24% 4.8 Mg Stearate 1% 20 Total 100% 2000 The physical mix formulation was prepared using a prior art method by (1) mixing all the ingredients except for magnesium stearate in a container, (2) mixing in magnesium stearate with the other ingredients, (3) compressing said ingredients with a Carver press at 3,000 psi.
To prepare the formulation of the present invention, a process of wet granulation was used. The steps in this example included (1) mixing piroxicam, mannitol, sodium hydroxide and water, (2) drying the mixture in an oven at 40 centigrade for 48 hours to form a dried paste, (3) grinding the dried paste, (4) mixing the paste with the remaining ingredients except for magnesium stearate, (5) adding magnesium stearate and mixing again, and (6) compressing said ingredients with a carver press at 3,000 PSI.
The physically mixed formulation (PM) and wet granulation formulation (WG) below, were administered oral transmucosally as part of an in vivo dog study. The results of the study are shown in Tables B-1 and B-2 below as well as in Figure 1.

Piroxicam Serum Concentration (ng/ml) After OT Delivery of Physical Mix Formulation in Dog Studies Time PM#1 PM#2 Average SD

0.00 0.00 0.00 0.00 0.00 5 40.01 25.74 32.88 10.09 10 176.68 149.78 163.23 19.02 15 289.08 231.90 260.49 40.43 20 316.51 278.19 297.35 27.10 25 307.93 257.80 282.87 35.45
17 Time PM#1 PM#2 Average SD

30 294.62 256.79 275.71 26.75 40 275.78 249.79 262.79 18.38 50 269.81 264.78 267.30 3.56 60 269.20 265.01 267.11 2.96 90 260.02 283.04 271.53 16.28 120 257.05 298.86 277.96 29.56 180 242.79 298.41 270.60 39.33 240 235.76 301.22 268.49 46.29 Cmax 316.51 278.19 297.35 27.10 tmax 20 20 20.00 0.00 AUC 59708.65 65969.975 62839.31 4427.43 Serum Piroxican Concentration (ng/ml) After OT Delivery of Wet Granulation Formulation in Dog Studies Time WG#1 WG#2 J Average SD

0.00 0.00 0.00 0.00 0.00 5 120.20 102.05 111.13 12.83 10 463.26 358.84 411.05 73.84 15 654.54 502.39 578.47 107.59 20 754.35 497.11 625.73 181.90 25 702.33 485.14 593.74 153.58 643.74 456.46 550.10 132.43 613.86 474.65 544.26 98.44 631.56 459.09 545.33 121.95 625.78 443.70 534.74 128.75 30 90 591.54 416.34 503.94 123.89 120 578.42 426.69 502.56 107.29 180 543.28 338.04 440.66 145.13
18 Time WG#1 WG#2 Average SD

240 484.20 329.63 406.92 109.30 Cmax 754.35 502.39 628.37 178.16 tmax 20 15 17.50 3.54 AUC 134169.15 93225.05 113697.10 28951.85 The data show an increase in both the maximum blood concentration, (Cmax), and bioavailability (AUC). The increase of the Cm,,, is more than two fold and the increase in AUC is almost two-fold. The data also show faster absorption into the blood stream (tmax)=
Example 2 In another experiment, the plasma concentrations of the drug droperidol delivered oral transmucosally using the present invention employing a co-melt technique were compared to those of droperidol delivered oral transmucosally using a prior art technique of physically mixing the drug formulation. The ingredients included droperidol, polyethylene glycol, citric acid in sorbitol, and solvent. The ingredients were mixed in the amounts shown in Table C.
TABLE C

Ingredient % mg/2g Droperidol 0.05% 1 Sorbitol 82.95% 1659 polyethyleneglycol (PEG) 15% 300 pH 6.0 Na2PH04/ citric acid (2:15:1) 2% 40 in sorbitol The prior art formulation was prepared by physically mixing the ingredients and compressing them into solid units. The present invention formulation was prepared by heating droperidol and PEG in a 90 C water bath until the PEG was melted.
The mixture was then cooled, solidified, and milled into powder. The co-melt powder was mixed with the other ingredients and compressed into solid units. The pharmaceutical agents were delivered oral transmucosally as part of an in vivo dog study. The blood plasma drug concentrations (Table D) of the subjects were measured over a period of 6 hours.
19 TABLE D
Plasma Droperidol Concentrations After OT Delivery to Dogs Droperidol Physical Mix vs. Co-Melt Time (min) Co-melt PM
0 0.00 0.00 5 0.00 0.00 0.00 0.03 0.21 0.06 0.10 0.07 10 25 0.03 0.33 0.06 45 0.47 0.08 60 0.29 0.04 90 0.28 0.17 15 120 0.18 0.00 180 0.15 0.04 240 0.14 0.01 300 0.12 0.01 360 0.13 0.05
20 Cmax 0.47 0.17 tmax 45 90 AUC (ng/ml*min) 62.89 13.26 As shown in Table D and in Figure 2, the data strongly suggest that the drug is absorbed 25 from the present invention at a higher rate and to a greater extent compared to the physical mix formulation. the present invention formulation is more readily absorbed and absorbed in higher quantities into the systemic circulation than the prior art formulation.
Example 3 30 In yet another experiment employing the co-melt process, the oral transmucosal delivery of the drug etomidate using the present invention was compared with delivery using prior art methods. The drug formulations were prepared using the ingredients Etomidate, PEG and Sorbitol. The amounts of each ingredient in the formulations are shown in Table E.

TABLE E

Ingredient % mg/2g Etomidate 1.25 25 PEG 74.06 1481.25 5 Sorbitol 24.69 493.75 The prior art formulation was prepared using a process of physical mixing. The present invention formulation was prepared using a co-melting process to create a solid solution containing etomidate. The two formulations were administered oral 10 transmucosally as part of an in vivo dog study. Serum concentrations of the drug were measured over a 90 minute period. The results are shown in Tables F-1 and F-2 and in Figure 3.

Serum Concentration (ng/n-A) of Etomidate after OT Delivery of Co-melt Formularion 15 Time (min) #4-200 #4-210 #4-222 Average S.D. R.S.D
0.0 0.00 0.00 0.00 0.00 0.00 5.0 103.98 93.00 111.89 102.95 9.48 9.21%
10.0 172.32 165.00 213.92 183.75 26.39 14.36%
12.5 138.13 156.00 210.04 168.06 37.44 22.28%

20 15.0 121.50 121.00 168.59 137.03 27.33 19.94%
17.5 77.06 71.00 104.53 84.20 17.87 21.22%
20.0 64.82 53.00 69.50 62.44 8.50 13.62%
25.0 41.70 31.00 43.22 38.64 6.66 17.24%
30.0 33.81 20.00 28.96 27.59 7.00 25.39%

45.0 21.33 15.00 17.63 17.99 3.18 17.67%
60.0 13.42 10.00 13.66 12.36 2.05 16.57%
90.0 9.97 0.00 0.00 3.32 5.75 173.21%
Cmax 172.32 165.00 213.92 183.75 Tmax 10 10 10 10.00 AUC 3568.76 2957.5 3907.74 3478.00
21 Serum Concentration (ng/ml) of Etomidate after OT Delivery of Physical Mix Formulation Time(min) #4-200 #4-210 #4-222 Average S.D. R.S.D
0.0 0.00 0.00 0.00 0.00 0.00 5.0 34.43 29.11 16.17 26.57 9.39 35.35%
10.0 103.12 81.86 46.59 77.19 28.55 36.99%
12.5 113.48 81.71 54.99 83.40 29.28 35.11%
15.0 87.68 85.63 50.67 74.66 20.80 27.86%
17.5 49.64 72.13 33.80 51.85 19.26 37.14%
20.0 32.97 28.41 16.91 26.10 8.28 31.71%
25.0 19.31 16.02 10.58 15.30 4.41 28.80%
30.0 19.02 0.00 9.51 13.45 141.42%
45.0 11.17 5.54 0.00 5.57 5.58 100.25%
60.0 0.00 0.00 0.00 0.00 90.0 0.00 0.00 0.00 0.00 0.00 Cmax 113.48 85.63 54.99 84.70 Tmax 12.5 15 12.5 13.33 AUC 1913.79 1511.14 720.523 1381.82 As with the other experiments, the data show that etomidate is absorbed at a faster rate and to a greater extent- (increased bioavailability) when delivcred using the present invention.

~

Claims (22)

WHAT IS CLAIMED IS:
1. A solid dosage form for oral transmucosal delivery of a pharmaceutical agent comprising:
(a) particles of a solid solution comprising a pharmaceutical agent mixed at the molecular level with a dissolution agent; and (b) a pH modifier physically mixed with the solid solution particles.
2. The solid dosage form of claim 1, wherein said pH modifier is a buffer.
3. The solid dosage form of claim 2, wherein said buffer is selected from the group consisting of phosphate buffer, carbonate buffer, tris buffer, tartrate buffer, borate buffer, acetate buffer, and maleate buffer.
4. The solid dosage form of claim 1, wherein said pharmaceutical agent is an organic acid.
5. The solid dosage form of claim 4, wherein said organic acid is in ionized form.
6. The solid dosage form of claim 1, wherein said pharmaceutical agent is an organic base.
7. The solid dosage form of claim 6, wherein said organic base is in ionized form.
8. The solid dosage form of claim 1, wherein said pharmaceutical agent is selected from the group consisting of androgen, estrogen, non-steroidal anti-inflammatory, anti-hypertensive, analgesic, antidepressant, antibiotic, anti-cancer, local anesthetic, antiemetic, antiinfective, contraceptive, antidiabetic, steroid, antiallergy, antimigraine, smoking cessation, and antiobesity agents.
9. The solid dosage form of claim 1, wherein said solid solution is prepared by the steps of:
(a) melting a dissolution agent;

(b) dissolving a pharmaceutical agent in the melted dissolution agent to form a solution; and (c) cooling the step (b) solution to form a solid solution.
10. The solid dosage form of claim 1, wherein said solid solution is prepared by the steps of:
(a) preparing a solution containing a pharmaceutical agent and a dissolution agent in a solvent; and (b) drying the solution to form a solid solution.
11. The solid dosage form of claim 10, wherein said solvent comprises water, and said drying step (b) comprises freeze-drying.
12. The solid dosage form of claim 10, wherein said drying step (b) comprises spray drying.
13. The solid dosage form- of claim 10, wherein said drying step (b) comprises oven drying.
14. The solid dosage form of claim 1, wherein said dissolution agent is selected from the group consisting of acacia, alginic acid, carbomer, carboxymethylcellulose calcium, carboxymethylcellulose sodium, microcrystalline cellulose, cellulose, dextrates, dextrin, dextrose, ethylcellulose, fructose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactitol, lactose, lecithin, maltodextrin, mannitol, methylcellulose, poloxamer, polyethylene glycol, polymethacrylates, polyoxyethylene alkyl ethers, polyvinyl alcohol, propylene glycol alginate, sodium alginate, sodium ascorbate, sodium starch glycolate, sorbitol, starch, pregelatinized starch, sucrose, tragacanth, trimethylglycine, xanthan gum, xylitol, and zein.
15. The solid dosage form of claim 1, wherein said dosage form is an oral transmucosal patch.
16. The solid dosage form of claim 1, wherein said dosage form is a lozenge.
17. The solid dosage form of claim 1, wherein said dosage form is a lozenge on a stick.
18. The solid dosage form of claim 1, wherein said dosage form is a chewing gum.
19. The solid dosage form of claim 1, further comprising at least one pharmaceutical ingredient selected from the group consisting of absorbents, colorants, flavorants, solvents, co-solvents, coating agents, direct compression excipients, disintegrants, glidants, lubricants, opaquants, polishing agents, suspending agents, sweetening agents, anti-adherents, binders, capsule diluents, anti-fungal preservatives, antimicrobial preservatives, clarifying agents, emulsifying agents, antioxidants, levigating agents, plasticizers, surfactants, tonicity agents, and viscosity increasing agents.
20. The solid dosage form of claim 1, wherein said pharmaceutical agent is selected from the group of piroxicam, droperidol, etomidate, nicotine, testosterone, estradiol, nitroglycerin, clonidine, dexamethasone, wintergreen oil, tetracaine, lidocaine, fentanyl, sufentanil, progesterone, insulin, Vitamin A, Vitamin C, Vitamin E, prilocaine, bupivacaine, sumatriptan, dihydroergotamine, COX2 inhibitors, and peptides.
21. The solid dosage form of claim 1, wherein said pharmaceutical agent is selected from the group consisting of methohexital, pentobarbital, thiamylal, thiopental, fentanyl, alfentanil, sufentanil, lofentanil, carfentanil, naloxone, nalbuphene, diazepam, lorazepam, midazolam, oxazepam, triazolam, droperidol, propanidid, etomidate, propofol, ketamine, diprivan, bretylium, captopril, clonidine, dopamine, enalapril, esmolol, furosemide, isosorbide, labetalol, lidocaine, metolazone, metoprolol, nadolol, nifedipine, nitroglycerin, nitroprusside, propranolol, benzquinamide, meclizine, metoclopramide, prochlorperazine, trimethobenzamide, clotrimazole, nystatin, carbidopa, levodopa, sucralfate, albuterol, amninophylline, beclomethasone, dyphylline, epinephrine, flunisolide, isoetharine, isoproterenol HCI, metaproterenol, oxtriphylline, terbutaline, theophylline, ergotamine, methysergide, propranolol, suloctidil, ergonovine, oxytocin, desmopressin acetate, lypressin, vasopressin, insulin, beta-endorphin, enkephalins, bradykinin, angiotensin I, gonadotropic hormones, adrenocorticotropic hormone, calcitonin, parathyroid hormone, growth hormone, polysaccharides, antigens, antibodies, and enzymes.
22. The solid dosage form of claim 1, wherein said pharmaceutical agent is a barbiturate, opioid agonist, benzodiazepine, butyrophenone, eugenol, GABA stimulator, substituted phenol, phencyclidine, antiarrhythmic, ACE inhibitor, antihypertensive, renal vascular, antihypertensive/angina, diuretic, angina, hypotensive, antiemetic, antifungal, antiparkinson with levodopa, antiparkinson, antisecretory, bronchodilator, antimigraine, oxytocic, antidiuretic, or antihyperglycemic.
CA002388610A 1999-10-27 2000-10-12 Oral transmucosal drug dosage using solid solution Expired - Fee Related CA2388610C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/428,071 1999-10-27
US09/428,071 US6264981B1 (en) 1999-10-27 1999-10-27 Oral transmucosal drug dosage using solid solution
PCT/US2000/028113 WO2001030288A1 (en) 1999-10-27 2000-10-12 Oral transmucosal drug dosage using solid solution

Publications (2)

Publication Number Publication Date
CA2388610A1 CA2388610A1 (en) 2001-05-03
CA2388610C true CA2388610C (en) 2007-08-21

Family

ID=23697434

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002388610A Expired - Fee Related CA2388610C (en) 1999-10-27 2000-10-12 Oral transmucosal drug dosage using solid solution

Country Status (12)

Country Link
US (1) US6264981B1 (en)
EP (1) EP1242013B2 (en)
JP (2) JP4815084B2 (en)
AT (1) ATE468845T2 (en)
AU (1) AU1079701A (en)
CA (1) CA2388610C (en)
DE (1) DE60044464D1 (en)
ES (1) ES2345870T5 (en)
HK (1) HK1050313A1 (en)
MX (1) MXPA02004235A (en)
PT (1) PT1242013E (en)
WO (1) WO2001030288A1 (en)

Families Citing this family (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19646392A1 (en) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6576250B1 (en) 1998-03-27 2003-06-10 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20020098264A1 (en) * 1998-11-27 2002-07-25 Cherukuri Subraman R. Medicated chewing gum delivery system for nicotine
US6358060B2 (en) * 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
GB0001710D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
CN100584322C (en) * 2000-10-11 2010-01-27 赛福伦公司 Compositions comprising modafinil compounds
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
DE60239528D1 (en) 2001-05-01 2011-05-05 Corium International Redwood City TWO-PHASE, WATER-ABSORBING BIOADHESIVE COMPOSITION
US8728445B2 (en) 2001-05-01 2014-05-20 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences Hydrogel Compositions
EP1390383B1 (en) * 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
ATE444060T1 (en) * 2001-06-22 2009-10-15 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS CONTAINING DISPERSIONS OF MEDICINAL SUBSTANCES AND NEUTRAL POLYMERS
SE521512C2 (en) * 2001-06-25 2003-11-11 Niconovum Ab Device for administering a substance to the front of an individual's oral cavity
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7854230B2 (en) * 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
DE60138494D1 (en) * 2001-11-29 2009-06-04 Rettenmaier & Soehne Gmbh & Co PROCESS FOR CO-SPRAY DRYING LIQUID HERB EXTRACTS WITH DRY SILIFIED MCC
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
ATE395044T1 (en) 2002-02-01 2008-05-15 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHIC DISPERSIONS OF ACTIVE INGREDIENTS AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
JP3931680B2 (en) * 2002-02-18 2007-06-20 株式会社日本自動車部品総合研究所 Straight traveling discrimination device for vehicle
US8017150B2 (en) * 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
CN101404892B (en) 2002-05-14 2012-04-04 Fmc有限公司 Microcrystalline cewllulose compositions
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
KR100548925B1 (en) * 2002-10-23 2006-02-02 한미약품 주식회사 Sustained release composition for oral administration of a drug
DE10251963A1 (en) * 2002-11-08 2004-05-19 Lts Lohmann Therapie-Systeme Ag Wafer-form transmucosal dosage form, comprising solution of active agent, e.g. for combating drug abuse, in phosphatidyl choline fraction, providing both rapid and constant release via the oral cavity
EP1575563B1 (en) * 2002-12-19 2007-02-14 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
FI3473251T3 (en) * 2002-12-20 2024-01-09 Niconovum Ab A nicotine-cellulose combination
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
CN1777411B (en) 2003-02-24 2013-01-02 药品生产公司 Transmucosal drug delivery system
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648981B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
JP4688787B2 (en) * 2003-02-28 2011-05-25 アルカベロ アクチェセルスカプ Dosage form with saccharide matrix
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
DK1631312T3 (en) * 2003-04-23 2009-01-19 Medarex Inc Composition and method of treatment for inflammatory bowel disease
US20040213828A1 (en) * 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
ATE461681T1 (en) 2003-04-29 2010-04-15 Gen Hospital Corp METHODS AND DEVICES FOR SUSTAINED RELEASE OF MULTIPLE DRUGS
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
CA2530843A1 (en) * 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
PL2446881T3 (en) * 2003-07-24 2014-08-29 Glaxosmithkline Llc Orally Dissolving Films
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US20050037194A1 (en) * 2003-08-15 2005-02-17 Kimberly-Clark Worldwide, Inc. Thermoplastic polymers with thermally reversible and non-reversible linkages, and articles using same
US20050042281A1 (en) * 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
GB0320854D0 (en) * 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US20050065175A1 (en) * 2003-09-24 2005-03-24 Xanodyne Pharmacal, Inc. Oral transmucosal methadone
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
EP1691631A4 (en) 2003-11-07 2012-09-05 Us Smokeless Tobacco Co Tobacco compositions
DE60305043T2 (en) * 2003-11-13 2006-11-30 Ferring B.V. Blister packaging and solid dosage form containing desmopressin
AU2012202628B2 (en) * 2003-11-19 2014-05-15 Salix Pharmaceuticals, Inc. Colonic purgative composition with soluble binding agent
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
AU2015221520B2 (en) * 2003-11-19 2017-06-08 Salix Pharmaceuticals, Inc. Colonic purgative composition with soluble binding agent
BRPI0418330A (en) * 2003-12-31 2007-05-02 Pfizer Prod Inc solid compositions of low solubility drugs and poloxamers
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
US20050142197A1 (en) * 2003-12-31 2005-06-30 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
DE602004031771D1 (en) * 2003-12-31 2011-04-21 Cima Labs Inc OPERATING FORM OF OPIATS FOR ORAL USE AND METHOD FOR THE ADMINISTRATION OF OXYCODONE
CA2551254A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
US7658721B2 (en) * 2004-01-16 2010-02-09 Biodel Inc. Sublingual drug delivery device
CN1929819B (en) 2004-01-30 2012-02-29 考里安国际公司 Rapidly dissolving film for delivery of an active agent
KR20150038745A (en) * 2004-02-17 2015-04-08 트랜스셉트 파마슈티칼스, 인코포레이티드 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
ES2398838T3 (en) * 2004-03-12 2013-03-22 Biodel, Inc. Fast-acting drug delivery compositions
US7850987B2 (en) * 2004-04-08 2010-12-14 Micronutrient, Llc Nutrient composition(s) and system(s) for individualized, responsive dosing regimens
US7785619B2 (en) * 2004-04-08 2010-08-31 Micro Nutrient, Llc Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
US20050226906A1 (en) * 2004-04-08 2005-10-13 Micro Nutrient, Llc Nutrient system for individualized responsive dosing regimens
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
KR20150041193A (en) * 2004-06-21 2015-04-15 메다렉스, 엘.엘.시. Interferon alpha receptor 1 antibodies and their uses
RU2393877C2 (en) 2004-08-05 2010-07-10 Кориум Интернэшнл, Инк. Adhesive composition
EP1789020A2 (en) 2004-08-31 2007-05-30 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
WO2006024284A2 (en) 2004-09-01 2006-03-09 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Atrium patch
DE102005003387A1 (en) * 2004-09-01 2006-03-02 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Plaster for administering active agents through body orifices, comprises adhesive and backing layers, both made of nonionic and anionic hydrocolloids in reverse ratios
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
CA2586760A1 (en) * 2004-11-05 2006-05-18 Edward S. Wilson Stabilized ramipril compositions and methods of making
US9198448B2 (en) * 2005-02-07 2015-12-01 Intercontinental Great Brands Llc Stable tooth whitening gum with reactive ingredients
DE102005015128B4 (en) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafers containing steroid hormones
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
CA2609330A1 (en) * 2005-05-25 2006-11-30 Transcept Pharmaceuticals, Inc. Solid compositions and methods for treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
PL1893157T3 (en) * 2005-06-03 2015-02-27 Teva Womens Health Inc Attachment of a handle to a solid oral dosage form.
DE102005033943A1 (en) * 2005-07-20 2007-02-22 Hexal Ag Non-spitting, oral, fast-disintegrating film for a neuroleptic
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2013059629A1 (en) 2011-10-21 2013-04-25 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
WO2007028247A1 (en) * 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7879382B2 (en) * 2005-09-30 2011-02-01 Fmc Corporation Stabilizers and compositions and products comprising same
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
CN101394863B (en) * 2006-01-06 2016-12-21 阿塞尔Rx制药有限公司 Small-volume oral transmucosal dosage forms
US8753308B2 (en) * 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8357114B2 (en) * 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
DE102006003512A1 (en) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Film-forming transmucosal medicament, useful for administering active agents such as androgens, gestagens and estrogens, comprises a film former, which disintegrates in an aqueous medium, and cyclodextrin or its derivatives
US20070172507A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
MX2008013165A (en) * 2006-04-12 2009-01-29 Biodel Inc Rapid acting and long acting insulin combination formulations.
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
US20070269492A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
US20070269386A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
US20070293582A1 (en) * 2006-06-05 2007-12-20 Malcolm Hill Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
WO2007143674A2 (en) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
DE102006027796A1 (en) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Flat form medicament preparation based on hydrophilic polymer disintegrates quickly in contact with moisture, useful e.g. to release active agent in body opening/body cavity e.g. for contraception, comprises active agent combination
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
KR101230804B1 (en) * 2006-07-21 2013-02-08 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 Transmucosal delivery devices with enhanced uptake
US8642016B2 (en) * 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
ATE493972T1 (en) * 2006-10-27 2011-01-15 Fmc Corp JOINTLY PROCESSED MICROCRYSTALLINE CELLULOSE AND SUGAR ALCOHOL AS AN EXCIPIENT FOR TABLET FORMULATIONS
CN101626750A (en) * 2007-01-05 2010-01-13 阿塞尔Rx制药有限公司 Storage and dispensing devices for administration of oral transmucosal dosage forms
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
WO2008098195A2 (en) * 2007-02-09 2008-08-14 Todd Maibach Film comprising nitroglycerin
AU2008216867B2 (en) * 2007-02-09 2014-01-30 Durect Corporation Transoral dosage forms comprising sufentanil and naloxone
CN104188907A (en) 2007-02-11 2014-12-10 Map药物公司 Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
WO2008124928A1 (en) * 2007-04-13 2008-10-23 Christopher Culligan Freezable unit dosage delivery system and method of preparation
WO2009037319A2 (en) * 2007-09-18 2009-03-26 Niconovum Ab Stable chewing gum compositions comprising maltitol and providing rapid release of nicotine
WO2009089181A1 (en) * 2008-01-04 2009-07-16 Blodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
WO2009091605A2 (en) * 2008-01-17 2009-07-23 Health Innovations, Llc Taste titration therapies
US20110082150A1 (en) * 2008-02-11 2011-04-07 Robert Owen Cook Headache pre-emption by dihydroergotamine treatment during headache Precursor events
AU2009214307A1 (en) * 2008-02-13 2009-08-20 Bayer Intellectual Property Gmbh Drug delivery system with stabilising effect
NZ586666A (en) * 2008-02-13 2012-04-27 Bayer Schering Pharma Ag Estradiol-containing drug delivery system
US20090269403A1 (en) * 2008-04-24 2009-10-29 Shaked Ze Ev Oral contraceptive dosage forms and methods of making such dosage forms
US20090298946A1 (en) * 2008-06-02 2009-12-03 Cleavelin Cody R Local Anesthetic Deactivation
CA2728912C (en) * 2008-06-23 2018-04-10 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
US8833378B2 (en) * 2008-09-17 2014-09-16 Niconovum Ab Process for preparing snuff composition
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US8784879B2 (en) 2009-01-14 2014-07-22 Corium International, Inc. Transdermal administration of tamsulosin
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
ES2554626T3 (en) 2009-06-12 2015-12-22 Cynapsus Therapeutics Inc. Sublingual apomorphine
RU2015144851A (en) 2009-06-18 2019-01-10 Серенити Фармасьютикалз, Элэлси SAFE APPLICATION OF DESMOPRESSIN
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
US9125858B2 (en) 2009-11-30 2015-09-08 Wilmore Labs L.L.C. Compositions and methods relating to resveratrol
US20120322884A1 (en) 2010-03-01 2012-12-20 University Of Manitoba Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
MX2013000284A (en) 2010-07-09 2013-03-18 Teijin Pharma Ltd Orally disintegrating tablet.
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) * 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695432B2 (en) * 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
KR102025238B1 (en) 2010-12-16 2019-09-25 선오비온 파마슈티컬스 인코포레이티드 Sublingual Films
DK3284459T3 (en) 2011-04-29 2021-03-15 Moberg Pharma Ab Pharmaceutical compositions comprising a local anaesthetic such as Bupivacaine for local administration to the mouth or throat
US9925264B2 (en) 2011-05-10 2018-03-27 Itochu Chemical Frontier Corporation Non-aqueous patch
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch
US9283174B2 (en) 2011-05-10 2016-03-15 Tatsuya Mori Non-aqueous patch
PE20141198A1 (en) 2011-09-19 2014-10-05 Orexo Ab NEW PHARMACEUTICAL COMPOSITION RESISTANT TO ABUSE FOR THE TREATMENT OF OPIOID DEPENDENCE
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
HUE039266T2 (en) 2011-09-27 2018-12-28 Itochu Chemical Frontier Corp Non-aqueous patch
EP2764046B1 (en) 2011-10-05 2021-04-21 DuPont Nutrition USA, Inc. Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
ES2657648T3 (en) 2011-10-05 2018-03-06 Fmc Corporation Stabilizing composition of microcrystalline cellulose and co-reduced carboxymethylcellulose, method for making it and uses
CN103987273B (en) 2011-12-09 2018-07-27 Fmc有限公司 The stabiliser compositions ground altogether with excellent glue intensity
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
MX356111B (en) 2012-04-18 2018-05-15 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions.
ME02644B (en) 2012-05-02 2017-06-20 Orexo Ab New alfentanil composition for the treatment of acute pain
EP3808339A1 (en) 2012-05-03 2021-04-21 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP2861224A4 (en) 2012-06-15 2015-11-18 Univ Nova Southeastern Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
FR2994844B1 (en) * 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris GELIFYING FORMULATION BASED ON KETAMINE
EP2919777B1 (en) * 2012-11-13 2020-01-08 Invictus Biotechnology Pty Ltd. Transmucosal delivery of tocotrienol
AU2013361337A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
SG11201505241WA (en) * 2013-01-14 2015-08-28 Infirst Healthcare Ltd Solid solution compositions and use in severe pain
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
ES2831625T3 (en) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Therapeutic compounds and their uses
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2014140868A2 (en) * 2013-03-15 2014-09-18 Allen Davidoff Xanthine oxidase inhibitor formulations
JP6255474B2 (en) 2013-03-15 2017-12-27 マリンクロッド エルエルシー Abuse deterrent solid dosage form for immediate release with functional secant
HUE055773T2 (en) 2013-03-22 2021-12-28 Univ Nova Southeastern Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
US11771127B2 (en) * 2013-10-03 2023-10-03 Altria Client Services Llc Chewable dissolvable nicotine tablet
US11779045B2 (en) * 2013-10-03 2023-10-10 Altria Client Services Llc Dissolvable-chewable exhausted-tobacco tablet
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2930410A1 (en) 2013-11-11 2015-05-14 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods of use
JP6310560B2 (en) 2013-12-17 2018-04-11 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. Laser printing system
EP3164117B1 (en) 2014-07-03 2023-09-06 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
MY187877A (en) 2014-12-23 2021-10-26 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
GB201504482D0 (en) * 2015-03-17 2015-04-29 King S College London Novel formulations
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US20180221384A1 (en) * 2015-07-16 2018-08-09 Swipp Ab Compositions of midazolam for buccal administration in the treatment of seizures to obtain rapid onset of action
EP3452023A1 (en) 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018127938A1 (en) * 2017-01-04 2018-07-12 Jubeln Lifesciences Pvt. Ltd. Oral dispersible film composition
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US10369157B1 (en) 2018-03-29 2019-08-06 Mfkc 200, Llc Multi-agent formulation
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
PL3962455T3 (en) 2020-05-18 2023-01-16 Orexo Ab New pharmaceutical composition for drug delivery
EP4236921A1 (en) 2021-11-25 2023-09-06 Orexo AB Pharmaceutical composition comprising adrenaline
WO2023187664A1 (en) * 2022-03-30 2023-10-05 Avaca Pharma Private Limited A pharmaceutical composition for the treatment of immune system mediated diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698822A (en) * 1951-04-28 1955-01-04 Fougera & Co Inc E Cardiac glycoside buccal composition
US3511914A (en) * 1967-01-31 1970-05-12 Schering Corp Throat lozenge vehicle
US3439089A (en) * 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
DD220225A5 (en) * 1983-03-16 1985-03-27 Boehringer Ingelheim Ltd PROCESS FOR PREPARING A SOLID-BODY DISPERSION OF CHLORO-THALIDONE
JPS6117510A (en) * 1984-07-03 1986-01-25 Toyobo Co Ltd Gradually releasing preparation of nifedipine to be applied to oral cavity mucosa
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4624849A (en) * 1984-11-02 1986-11-25 The Procter & Gamble Company Antimicrobial lozenges
US5132114A (en) 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
SE448889B (en) * 1985-11-06 1987-03-23 Sunds Defibrator SET FOR TREATMENT OF RECOVERY PAPERS
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
IT1227626B (en) * 1988-11-28 1991-04-23 Vectorpharma Int SUPPORTED DRUGS WITH INCREASED DISSOLUTION SPEED AND PROCEDURE FOR THEIR PREPARATION
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
JP3773062B2 (en) * 1993-01-29 2006-05-10 味の素株式会社 Pharmaceutical additives
US5741523A (en) 1993-10-27 1998-04-21 Pharmacia & Upjohn Company Stabilized prostaglandin E1
DE19509807A1 (en) 1995-03-21 1996-09-26 Basf Ag Process for the preparation of active substance preparations in the form of a solid solution of the active substance in a polymer matrix, and active substance preparations produced using this method
IT1274034B (en) 1994-07-26 1997-07-14 Applied Pharma Res PHARMACEUTICAL COMPOSITIONS BASED ON RUBBER TO BE CHEWED AND PROCEDURE FOR THEIR PREPARATION
JPH08291063A (en) * 1995-04-21 1996-11-05 Maruho Kk Readily absorbable pharmaceutical preparation and its production
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
JP3460538B2 (en) * 1997-10-08 2003-10-27 救急薬品工業株式会社 Fast dissolving film preparation

Also Published As

Publication number Publication date
EP1242013A4 (en) 2005-06-15
PT1242013E (en) 2010-07-14
DE60044464D1 (en) 2010-07-08
MXPA02004235A (en) 2004-04-21
EP1242013B1 (en) 2010-05-26
EP1242013B2 (en) 2017-12-06
CA2388610A1 (en) 2001-05-03
HK1050313A1 (en) 2003-06-20
JP2008201805A (en) 2008-09-04
ES2345870T5 (en) 2018-02-12
US6264981B1 (en) 2001-07-24
ES2345870T3 (en) 2010-10-05
JP2003512402A (en) 2003-04-02
EP1242013A1 (en) 2002-09-25
WO2001030288A1 (en) 2001-05-03
AU1079701A (en) 2001-05-08
JP4815084B2 (en) 2011-11-16
ATE468845T2 (en) 2010-06-15

Similar Documents

Publication Publication Date Title
CA2388610C (en) Oral transmucosal drug dosage using solid solution
US8992974B2 (en) Transmucosal drug delivery system
RU2201216C2 (en) Rapidly cleaving pharmaceutical medicinal form
US20160256415A1 (en) Transmucosal ketamine delivery composition
US9358296B2 (en) Transmucosal drug delivery system
US9549897B2 (en) Transmucosal hormone delivery system
US20050065175A1 (en) Oral transmucosal methadone
EP1773292B1 (en) Rapidly disintegrating orodispersible composition containing nonfilamentous coprocessed polyols particles and silicified microcrystalline cellulose
WO2020180608A1 (en) Dipivefrin orally disintegrating tablet formulations
US20170056320A1 (en) Transmucosal drug delivery system
KR20040045499A (en) Flashmelt Oral Dosage Formulation
US20140303227A1 (en) Transmucosal hormone delivery system
US20150080442A1 (en) Transmucosal drug delivery system
US20140256765A1 (en) Transmucosal drug delivery system
US20140256822A1 (en) Transmucosal drug delivery system
WO2020121027A1 (en) Amorphous alprazolam compositions with anxiolytic activity with ethyl cellulose and crospovidone and corresponding methods
US20140303128A1 (en) Transmucosal hormone delivery system
AU2004216098B2 (en) Transmucosal drug delivery system

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20191015